Isolation and Enumeration of Circulating Endothelial Cells with Antibody-Labeled Staggered Herringbone Microfluidic System.

Md Mahedi Hasan, Angel Ricardo Lerma, Taslim A Al-Hilal

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Md Mahedi HasanDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.

Angel Ricardo LermaDepartment of Molecular Pharmaceutics, University of Utah, Salt Lake City, UT, USA.

Taslim A Al-HilalDepartment of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. taslim.al-hilal@pharm.utah.edu.

Funding

Targeting of Doppel-axis to Control Lung Tumor Angiogenesis and ImmunityR01CA262788 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Taslim A Al-Hilal · 2022 to 2026

$1.4M

The role of tumor endothelium-specific prion-gene PRND in epithelial ovarian cancerR21CA264627 · NCI · UNIVERSITY OF UTAH · PI AL-HILAL, TASLIM A · 2022 to 2023

$387k

NCI NIH HHS R01 CA262788NCI NIH HHS R21 CA264627

6 · The paper itself

Abstract

Circulating endothelial cells (CECs) are a key indicator of cardiovascular dysregulation. It is possible to efficiently isolate live CECs from patient blood samples for subsequent analysis by using microfluidic systems. Antibody-based methods ensure efficient and high-accuracy isolation of CECs. By performing this isolation under septic conditions, it is possible to collect viable CECs, which can then be cultured for further study. In this work, we detail the process of isolating and enumerating CECs from patient blood using biotinylated x-hu anti-CD31 antibody-coated staggered herringbone (μ-HB) devices.

Indexed as

AntibodiesCell SeparationEndothelial CellsLab-On-A-Chip DevicesMicrofluidic Analytical TechniquesMicrofluidicsHumansPlatelet Endothelial Cell Adhesion Molecule-1AntibodiesPlatelet Endothelial Cell Adhesion Molecule-1Antibody-coated microfluidicsCardiovascular dysfunctionCirculating biomarkersCirculating endothelial cellHerringbone deviceMicrofluidic cell isolation

Identifiers

PMID40859072

DOI10.1007/978-1-0716-4706-6_3

PMCPMC13360855

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.